Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis [0.03%]
局限期小细胞肺癌患者的长期生存数据：一项回顾性分析
Kosei Doshita,Hirotsugu Kenmotsu,Shota Omori et al.
Kosei Doshita et al.
Introduction: In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival data have not been fully evaluated. Moreover, the association between lo...
Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma [0.03%]
更正：从一个大型天然产物库中鉴定和表征用于多发性骨髓瘤 Aurora A 激酶的脱氯氯噻灵霉素
Nadire Özenver,Sara Abdelfatah,Anette Klinger et al.
Nadire Özenver et al.
Published Erratum
Investigational new drugs. 2022 Apr;40(2):462. DOI:10.1007/s10637-021-01193-4 2022
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study [0.03%]
校正信息：Selinexor联合托泊替康治疗晚期或转移性实体瘤患者：一项开放标签、单中心、多组别Ⅰb期研究的结果
Kyaw Zin Thein,Sarina A Piha-Paul,Apostolia Tsimberidou et al.
Kyaw Zin Thein et al.
Published Erratum
Investigational new drugs. 2022 Apr;40(2):461. DOI:10.1007/s10637-021-01192-5 2022
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells [0.03%]
FX1是一种BCL6抑制剂，可重新激活BCL6靶基因并抑制HTLV-1感染的T细胞
Chie Ishikawa,Naoki Mori
Chie Ishikawa
Human T cell leukemia virus type 1 (HTLV-1) is responsible for adult T cell leukemia (ATL); however, molecular and cellular mechanisms underlying HTLV-1-induced leukemogenesis are unclear. BCL6 oncogene is involved in cancer progression and...
Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma [0.03%]
白三烯B4受体2与透明细胞肾细胞癌的预后和免疫浸润相关
Xia Yuan,Yi He,Chenhui Luo et al.
Xia Yuan et al.
Background: Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. According to reports, leukotriene B4 receptor 2 (LTB4R2, also known as BLT2), a chemokine receptor, is upregulated in different tumors. ...
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial [0.03%]
注射用苯并霉素脂质体治疗中国晚期乳腺癌患者的有效性和安全性：随机、开放标签、阳性对照、单中心Ⅱ期临床试验
Leiping Wang,Jun Cao,Chunlei Li et al.
Leiping Wang et al.
Purpose: This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC). ...
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer [0.03%]
durvalumab治疗后局部晚期非小细胞肺癌患者肺炎的预后影响
Ari Nishimura,Akira Ono,Kazushige Wakuda et al.
Ari Nishimura et al.
Background: Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic implicati...
Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma [0.03%]
泽鲁邦是一种头颈部鳞状细胞癌的增敏剂
Julia Schnoell,Isabella Stanisz,Bernhard J Jank et al.
Julia Schnoell et al.
Introduction: Zerumbone is a phytochemical compound of the ginger plant Zingiber zerumbet with cytotoxic effects in various cancer cell lines. To date, zerumbone has shown an antiproliferative effect in oral squamous cell...
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors [0.03%]
OBP-801的Ia期剂量爬坡研究，一种环状多肽组蛋白去乙酰化酶抑制剂，在晚期实体瘤患者中的应用
Elisabeth I Heath,Amy Weise,Ulka Vaishampayan et al.
Elisabeth I Heath et al.
Background Dysregulation of histone deacetylases (HDACs) is common in cancer and is critical to the development and progression of the majority of tumors. This first-in-human Phase Ia study assessed the safety, efficacy, and pharmacokinetic...
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer [0.03%]
CDK4抑制剂Fascaplysin与EGFR抑制剂Afatinib联用对非小细胞肺癌的协同细胞毒作用
Adelina Plangger,Barbara Rath,Maximilian Hochmair et al.
Adelina Plangger et al.
In the absence of suitable molecular markers, non-small cell lung cancer (NSCLC) patients have to be treated with chemotherapy with poor results at advanced stages. Therefore, the activity of the anticancer marine drug fascaplysin was teste...